NorthWest Biotherapeutics Inc (NWBO)

[sentiment_stocks]

treatment is continued under the provision that a confirmatory scan be performed 2 months later (ie, 12 weeks after radiotherapy) ...
If the investigator observes a =25% increase in index lesions and/or unequivocal progression of existing nonindex lesions relative to the baseline disease assessment, then the recommended assessment is pseudoprogression, and treatment is continued under the provision that a confirmatory scan be performed 2 months later (ie, 12 weeks after radiotherapy) (Fig. 3). If the confirmatory scan shows further tumor progression as compared to the previous MRI, the assessment is PD, and the patient is discontinued from further treatment. In such cases, the date of the first disease assessment after radiotherapy is considered to be the date of PD.

I would very much love for you to be right. And I'm sure even Avii can attest to how much I would like that.

I just wish the April 2013 protocol said the same thing. But it doesn't. All it does is cite the 2010 paper in a footnote. It seems very specific as to how it will determine progression.